Work

Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4216

Authors: Meghana Singh, Naudia L. Jonassaint, John C. Rhee, Vikram C. Gorantla, Ibrahim Halil Sahin, Janie Yue Zhang, Dennis Hsu, Stela Celaj, Scott W. Biggins, Satdarshan Monga, Aatur D. Singhi, David A. Geller, Anwaar Saeed

Institutions: University of Pittsburgh Medical Center, University of Pittsburgh, UPMC Hillman Cancer Center, UPMC Health System

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Exelixis

OpenAlex ID: W4410815775

FWCI: 0.497

Cites:

Cited by: 1

Related to: 10